Dr.B.Anil Reddy Maheshwara College of Pharmacy, Department of Pharmaceutical sciences, Hyderabad, Andhra Pradesh, Volume-3
2) Gheorghiade M, Van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the
management of cardiovascular disorders. Circulation 2006;113:2556–2564. https://doi.
org/10.1161/CIRCULATIONAHA.105.560110
3) Bavendiek U, Davilla LA, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099.
4) Buckalew, V.M (2005). Endogenous digitalis-like factors. An historical overview. Front Biosci 1,Vol.0:2325-2334.
5) McGuffin M, Hobbs C, Upton R, Goldberg A,eds (1997). American Herbal Products Association's Botanical Safety Handbook.Boca Raton, FL: CRC Press.
6) Shumaik GM, Wu AW, Ping AC (1988). Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med. Vol.17:732-735.
7) Dick M, Curwin J, Tepper D (1991). Digitalis intoxication recognition and management. J Clin Pharmacol .Vol.31:444-447.
8) Buckalew, V.M (2005). Endogenous digitalis-like factors. An historical overview. Front Biosci 1,Vol.0:2325-2334.
9) Dec GW (2003). Digoxin remains useful in the management of chronic heart failure. Med Clin North Am .Vol.87:317
10) Wickersham RM, Novak K (2004), managing eds. Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons
11) Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Cleason P(2001). Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. Vol. 12:475-483
12) Kotecha D, Bunting K, Gill SK, Mehta S, Stanbury M, Jones JC, et al. For the RATE-HF team. Effect of digoxin vs. bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life. The RATE-HF randomized clinical trial. JAMA 2020; 324:2497–2508. https://doi.org/10.1001/jama.2020.23138
13) Van Veldhuisen DJ. Low-dose digoxin in patients with heart failure: less toxic and at least as effective? J Am Coll Cardiol 2002;39:954–956. https://doi.org/10.1016/S0735-1097(02) 01710-2
14) Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Drab A, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med., 2000 Sep; 18(5): 517-74.
15) Mutnick AH. Digoxin. In G. E. Schumacher (Ed.), Therapeutic drug monitoring (469–491). Norwalk: Appleton & Lange, 1995.
16) Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.Effects of candesartan on mortality and morbidity in patients with chronic heartfailure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
17) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
18) Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
19) Ather S, Peterson LE, Divakaran VG, Deswal A, Ramasubbu K, Giorgberidze I, Blaustein A, Wehrens XHT, Mann DL, Bozkurt B. Digoxin Treatment in Heart Failure - Unveiling Risk by Cluster analysis of DIG data. Int J Cardiol 2011; 150:264-269.
20) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
21) Remme WJ, Swedberg K. On behalf of the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527–1560. https://doi.org/10. 1053/euhj.2001.2783
22) Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcome in patients with heart failure. JAMA 2003;289: 871–878. https://doi.org/10.1001/jama.289.7.871
23) Bavendiek U, Davilla LA, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017;38:2095–2099.